First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.
RADICAVA (edaravone) Indicated for All Adult Patients Diagnosed with ALS JERSEY CITY, N.J., Aug. 8, 2017 -- (Healthcare Sales &Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA (edaravone), an intravenous therap... Biopharmaceuticals, Neurology, Product Launch Mitsubishi Tanabe Pharma, RADICAVA, edaravone, amyotrophic lateral sclerosis
(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Xueping Chen, Qian-Qian Wei, Yongping Chen, Bei Cao, RuWei Ou, Yanbing Hou, Xiaoqin Yuan, Lingyu Zhang, Hui Liu, Huifang Shang
Publication date: Available online 18 June 2018 Source:Molecular and Cellular Neuroscience Author(s): Rachit Bakshi, Yuehang Xu, Kaly A. Mueller, Xiqun Chen, Eric Granucci, Sabrina Paganoni, Ghazaleh Sadri-Vakili, Michael A. Schwarzschild Dominant mutations in an antioxidant enzyme superoxide dismutase-1 (SOD1) cause amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease characterized by loss of motor neurons. Oxidative stress has also been linked to many of the neurodegenerative diseases and is likely a central mechanism of motor neuron death in ALS. Astrocytes derived from mutant SOD1 G93A mouse m...
The S-oxidation of S-carboxymethyl-L-cysteine has been reported previously to be a biomarker of disease susceptibility in Parkinson ’s disease and Amyotrophic lateral sclerosis. In this investigation, the original observations have been confirmed with the incidence of the poor metaboliser phenotype (no urinary recovery of S-oxide metabolites) being found to be 3.9% within healthy control population. However, 38.3% of the Parki nson’s disease subjects and 39.0% of the Amyotrophic lateral sclerosis group were phenotyped as poor metabolisers.
Publication date: Available online 19 June 2018 Source:The Lancet Neurology Author(s): Albert C Ludolph, Joachim Schuster, Johannes Dorst, Luc Dupuis, Jens Dreyhaupt, Jochen H Weishaupt, Jan Kassubek, Ulrike Weiland, Susanne Petri, Thomas Meyer, Julian Grosskreutz, Berthold Schrank, Matthias Boentert, Alexander Emmer, Andreas Hermann, Daniel Zeller, Johannes Prudlo, Andrea S Winkler, Torsten Grehl, Michael T Heneka, Siw Wollebæk Johannesen, Bettina Göricke Background Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD...
Conditions: Amyotrophic Lateral Sclerosis; Primary Lateral Sclerosis; Kennedy's Disease Intervention: Sponsors: Assistance Publique - Hôpitaux de Paris; Centre National de la Recherche Scientifique, France Not yet recruiting
(AcuraStem, Inc.) AcuraStem, a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a 3.7 million dollar Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, 'AS2015', focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72.
In conclusion, the present findings demonstrate abnormal alternative splicing of ATG4B transcripts in ALS neural tissue in agreement with TARDBP loss of function, leading to impaired autophagy. PMID: 29912613 [PubMed - as supplied by publisher]
Publication date: 1 August 2018 Source:Neuroscience, Volume 384 Author(s): Maria Meyer, Agustina Lara, Hazel Hunt, Joseph Belanoff, E. Ronald de Kloet, Maria Claudia Gonzalez Deniselle, Alejandro F. De Nicola Wobbler mice are experimental models for amyotrophic lateral sclerosis. As such they show motoneuron degeneration, motor deficits, and astrogliosis and microgliosis of the spinal cord. Additionally, Wobbler mice show increased plasma, spinal cord and brain corticosterone levels and focal adrenocortical hyperplasia, suggesting a pathogenic role for glucocorticoids in this disorder. Considering this endocrine backgroun...
Conclusions: Empathy develops and operates within shared experiences and connections, enabled by structural possibilities provided by the forums giving users the opportunity and means to interact within public, restricted, and more private spaces, as well as within groups and in one-to-one exchanges. The atmosphere and feeling of both sites and perceived audiences were important facilitators of empathy, with users sharing a perception of virtual communities of caring and supportive people. Our findings are of value to organizations hosting health forums and to health professionals signposting patients to additional sources of support.